With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.
The resulting compound (113 mg, 0.350 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (68.6 mg, 0.350 mmol) to afford the desired title compound (107 mg, yield 66%) as a yellow solid. 1H-NMR (DMSO-d6, 400 MHz) delta: 12.85 (1H, brs), 9.56 (1H, m), 7.87 (1H, dd, J=8.2 Hz, 7.8 Hz), 7.78 (2H, d, J=9.0 Hz), 7.65 (1H, dd, J=7.8 Hz, 7.4 Hz), 7.40 (1H, d, J=7.4 Hz), 7.38 (1H, d, J=8.2 Hz), 7.19 (2H, dd, J=9.0 Hz, 4.2 Hz), 5.00 (1H, m), 4.83 (1H, m), 4.07-3.81 (2H, m), 3.61-3.16 (2H, m), 2.14-1.46 (6H, m), 0.92 (3H, t, J=7.4 Hz). IR (KBr) cm-1: 2965, 2220, 1685, 1630, 1505, 1250. MS (ESI, m/z): 460 (M+H)+. HRMS (ESI, m/z): 460.1973 (Calcd for C25H26N5O4: 460.1984).
1204-75-7, The synthetic route of 1204-75-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider